Recruiting NA INTERVENTIONAL 2-arm NCT06267391

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (ReCET)

A Multicenter, Randomized, Double-blind, Sham-controlled Study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (ReCET Study)

Sponsor: Endogenex, Inc.

Conditions Diabetes Diabetes Mellitus, Type 2 Type 2 Diabetes Type 2 Diabetes Mellitus Type2diabetes

Interventions ReCET Treatment Sham Procedure

Updated 5 times since 2024 Last updated: Aug 11, 2025 Started: May 1, 2024 Primary completion: Apr 1, 2026 Completion: Oct 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Diabetes and Diabetes Mellitus, Type 2, this trial is actively recruiting participants. The trial is conducted by Endogenex, Inc. and has accumulated 5 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Recruiting NA
Apr 2025 — Sep 2025 [monthly]

Recruiting NA
Sep 2024 — Apr 2025 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting NA
Mar 2024 — Jul 2024 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Endogenex, Inc.

Data source: Endogenex, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Baltimore, United States , Bellaire, United States , Birmingham, United States , Box Hill, Australia , Camden, United States , Camperdown, Australia , Clive, United States , Columbus, United States , Dallas, United States and 25 more locations